Pamela L. Kunz

Clinical Trials

• Not Recruiting A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
• Not Recruiting Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
• Not Recruiting Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
• Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
• Not Recruiting Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
• Not Recruiting A Study of MM-111 and Paclitaxel With or Without Trastuzumab in Patients HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
• Not Recruiting A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
• Not Recruiting TELESTAR (Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome)
• Recruiting Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
• Recruiting Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
• Recruiting Immunotherapy Study for Surgically Resected Pancreatic Cancer
• Not Recruiting Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
• Not Recruiting AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
• Not Recruiting Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
• Not Recruiting A Study of Nilotinib Versus Imatinib in GIST Patients
• Not Recruiting PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
• Not Recruiting Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
• Not Recruiting Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
• Not Recruiting A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
• Not Recruiting A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
• Not Recruiting Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
• Not Recruiting Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer
• Not Recruiting S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
• Not Recruiting Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
• Not Recruiting A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
• Not Recruiting Phase 1 Trial of Oral Ixabepilone
• Not Recruiting A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
• Not Recruiting A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
• Not Recruiting Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project
• Recruiting Phase IIa Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
• Recruiting Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
• Recruiting Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors